• Login
• Admin

Article

Backen, Alison C., Lopes, Andre, Wasan, Harpreet, Palmer, Daniel H., Duggan, Marian, Cunningham, David, Anthoney, Alan, Corrie, Pippa G., Madhusudan, Srinivasan, Maraveyas, Anthony, Ross, Paul J., Waters, Justin S., Steward, William P., Rees, Charlotte, McNamara, Mairéad G., Beare, Sandy, Bridgewater, John A., Dive, Caroline and Valle, Juan W. (2018) Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. British Journal of Cancer . ISSN 0007-0920

Ghaneh, Paula, Hanson, Robert, Titman, Andrew, Lancaster, Gill, Plumpton, Catrin, Lloyd-Williams, Huw, Tien Yeo, Seow, Edwards, Rhiannon T., Johnson, Colin, Hilal, Mohammed Abul., Higginson, Antony P., Armstrong, Tom, Smith, Andrew, Scarsbrook, Andrew, McKay, Colin, Carter, Ross, Sutcliffe, Robert P., Bramhall, Simon, Kocher, Hemant M., Cunningham, David, Pereira, Stephen P., Davidson, Brian, Chang, David, Khan, Saboor, Zealley, Ian, Sarker, Debashis, Al Sarireh, Bilal, Charnley, Richard, Lobo, Dileep N., Nicolson, Marianne, Halloran, Christopher, Raraty, Michael, Sutton, Robert, Vinjamuri, Sobhan, Evans, Jonathan, Campbell, Fiona, Deeks, Jon, Sanghera, Bal, Wong, Wai-Lup and Neoptolemos, John P. (2018) PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. Health Technology Assessment, 22 (7). ISSN 1366-5278

Middleton, Gary, Palmer, Daniel H., Greenhalf, William, Ghaneh, Paula, Jackson, Richard, Cox, Trevor, Evans, Anthony, Shaw, Victoria E., Wadsley, Jonathan, Valle, Juan W., Propper, David, Wasan, Harpreet, Falk, Stephen, Cunningham, David, Coxon, Fareeda, Ross, Paul, Madhusudan, Srinivasan, Wadd, Nick, Corrie, Pippa, Hickish, Tamas, Costello, Eithne, Campbell, Fiona, Rawcliffe, Charlotte and Neoptolemos, John P. (2017) Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. Lancet Oncology, 18 (4). pp. 486-499. ISSN 1474-5488

Valle, Juan W., Wasan, Harpreet, Lopes, Andre, Backen, Alison C., Palmer, Daniel H., Morris, Karen, Duggan, Marian, Cunningham, David, Anthoney, D. Alan, Corrie, Pippa, Srinivasan, Narayanan, Maraveyas, Anthony, Ross, Paul J., Waters, Justin S., Steward, Will P., Rees, Charlotte, Beare, Sandy, Dive, Caroline and Bridgewater, John A. (2015) Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncology, 16 (8). pp. 967-978. ISSN 1474-5488

Middleton, Gary, Silcocks, Paul, Cox, Trevor, Valle, Juan, Wadsley, Jonathan, Propper, David, Coxon, Fareeda, Ross, Paul, Srinivasan, Madhusudan, Roques, Tom, Cunningham, David, Falk, Stephen, Wadd, Nick, Harrison, Mark, Corrie, Pippa, Iveson, Tim, Robinson, Angus, McAdam, Karen, Eatock, Martin, Evans, Jeff, Archer, Caroline, Hickish, Tamas, Garcia-Alonso, Angel, Nicolson, Marianne, Steward, William, Anthoney, D. Alan, Greenhalf, William, Shaw, Victoria E., Costello, Eithne, Naisbitt, Dean, Rawcliffe, Charlotte, Nanson, Gemma and Neoptolemos, John P. (2014) Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncology, 15 (8). pp. 829-840. ISSN 1474-5488

Ford, Hugo, Marshall, Andrea, Bridgewater, John A., Janowitz, Tobias, Coxon, Fareeda, Wadsley, Jonathan, Mansoor, Wasat, Fyfe, David, Madhusudan, Srinivasan, Middleton, Gary, Swinson, Daniel, Falk, Stephen, Chau, Ian, Cunningham, David, Kareclas, Paula, Cook, Natalie, Blazeby, Jane M. and Dunn, Janet A. (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncology, 15 (1). pp. 78-86. ISSN 1474-5488